Statins
14 Nov Statins May Impede Growth of Uterine Fibroids
MedicalResearch.com Interview with:
Mostafa Borahay, MD, FACOG
Assistant Professor, Director of Simulation Education
Department of Obstetrics and Gynecology
University of Texas Medical BranchCo-director of Minimally Invasive Gynecologic Surgery University of Texas Medical Branch
Medical Research: What is the background for this study? What are the main findings?
Dr. Borahay: Uterine fibroids are the most common type of tumor in the female reproductive system, accounting for half of the 600,000 hysterectomies done annually in the U.S. Their estimated annual cost is up to $34 billion in the U.S. alone. Despite this, the exact cause of these tumors is not well understood, as there are several genetic, familial and hormonal abnormalities linked with their development. Even more, we currently don’t have a satisfactory medical treatment for these tumors.
Our team investigated the impact of simvastatin on human uterine fibroid cell growth. Statins, such as simvastatin, are commonly prescribed to lower high cholesterol levels. Statins work by blocking an early step in cholesterol production. Beyond these well-known cholesterol-lowering abilities, statins also combat certain tumors. Statins have previously been shown to have anti-tumor effects on breast, ovarian, prostate, colon, leukemia and lung cancers. However, the effect of statins on uterine fibroids was unknown.
We found that simvastatin impedes the growth of uterine fibroid tumor cells. We also studied the way simvastatin works to suppress these tumors. Simvastatin was shown to inhibit ERK phosphorylation, which is a critical step in the molecular pathway that prompts the growth of new cells. In addition, simvastatin stops the progression of tumor cells that have already begun to grow and induces calcium-dependent cell death mechanisms in fibroid tumor cells. Therefore, we identified a novel pathway by which simvastatin induces the death of uterine fibroid tumor cells.
22 Sep Statins May Have Additional Lipid Profile Benefit in Pre-Diabetes
\MedicalResearch.com Interview with: Prof. Moses Elisaf Professor of Internal Medicine University of Ioannina, Greece Medical Research: What are the main findings of the study? Dr. Elisaf: We evaluated the effects of rosuvastatin in two groups of hyperlipidemic patients: one group had impaired fasting glucose (IFG) while the second group had normal fasting glucose. After study end, both groups had similar changes in their lipidemic profile. However, patients with IFG had a significant greater decrease in the cholesterol concentration of the more atherogenic small dense low-density lipoprotein (sdLDL) particles (-65.7%) compared with controls (-38.5%). Moreover, a greater increase in the mean LDL particle size was observed in the impaired fasting glucose group (+1.5% vs +0.4%). In addition, redistribution from the more atherogenic sdLDL to large buoyant LDL (lbLDL) subfractions was observed in the IFG group.11 Sep Diabetics on Statins May Have Fewer Microvascular Complications
MedicalResearch.com Interview with: Børge G. Nordestgaard, MD, DMSc Professor, University of Copenhagen Chief Physician, Herlev Hospital, Copenhagen University Hospital Dept. Clinical Biochemistry Herlev Ringvej Herlev, Denmark Medical Research: What are the main findings of the study? Dr. Nordestgaard: Among all patients with diabetes in Denmark during 1996-2009 and compared with non-statin users, statin users had a 40% lower risk of diabetic retinopathy, a 34% lower risk of diabetic neuropathy, and a 12% lower risk of gangrene of the foot, while the risk of diabetic nephropathy was similar.25 Jun Surprising Number of Patients Do Not Take Their Prescribed Statin Medication
MedicalResearch.com Interview with: Dr. Heli Halava: Departments of Public Health and Pharmacology, Turku, Finland MedicalResearch: What are the main findings of the study? Dr. Halava: The associations between lifestyle factors and nonadherence to statin therapy varied by cardiovascular comorbidity status. Of the participants without cardiovascular comorbidities (n = 6458), 3171 (49.1%) were nonadherent with their statin therapy. Of the participants with cardiovascular comorbidities (n = 2827), 1155 (40.9%) were nonadherent. People with cardiovascular comorbidities who had risky drinking behaviours or a cluster of lifestyle risks were at increased risk of nonadherence.10 Jun Older Men Taking Statins Less Physically Active
MedicalResearch.com Interview with
David S.H. Lee, Pharm.D., Ph.D.
Assistant Professor
Department of Pharmacy Practice
College of Pharmacy
Oregon State University/Oregon Health and Science University
Portland OR, 97239
MedicalResearch: What are the main findings of the study?
Dr. Lee: We found that older men taking a statin were less physically active and had more sedentary behavior. They had about 37 minutes of less moderate exercise per week. For comparison, the American heart Association recommends about 40 minutes of moderate activity 3-4 times per week. We also found that those that started using a statin during the study had the largest drop in physical activity.
22 May Statins for Sepsis-Associated Acute Respiratory Distress Syndrome?
MedicalResearch.com Interview with:
Jonathon D. Truwit, MD, MBA
Enterprise Chief Medical Officer
Sr. Administrative Dean
Froedtert-Medical College of Wisconsin
Milwaukee, WI 53226
MedicalResearch.com: What are the main findings of the study?
Dr. Truwit: Rosuvastatin did not reduce mortality, nor days free of the breathing machine, in patients with sepsis-associated acute respiratory distress syndrome (ARDS). One in four patients with ARDS die.
20 May Are Statins Effective In Reducing COPD Flares?
MedicalResearch Interview with:
Dr. Gerard J. Criner MD, FACP, FACCP
Professor, Medicine
Director, Medical Intensive Care Unit and Ventilator Rehabilitation Unit
Co-Director, Center for Inflammation, Translational and Clinical Lung Research, Temple University Hospital in Philadelphia, PA
MedicalResearch: What are the main findings of the study?
Dr. Criner: The STATCOPE Trial (Simvastatin in the Prevention of COPD Exacerbations) found that a statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD). The study rigorously tested the hypothesis that statin drugs may be beneficial to persons with COPD because of the drugs’ purported anti-inflammatory effect. However, researchers found that:
- 40 mg. of daily simvastatin (statin drug) added to usual care did not reduce exacerbation rate or prolong the time to exacerbation in patients with moderate to severe COPD.
- Simvastatin had no effect on lung function, quality of life, severe adverse events or mortality.
- The data do not demonstrate a therapeutic benefit from statins in patients with moderate to severe COPD.
14 May Evolocumab for LDL Cholesterol Reduction in Statin-Treated Patients
Medi
calResearch.com Interview with:
Jennifer G. Robinson, MD, MPH
Professor ,Departments of Epidemiology & Medicine
Director, Prevention Intervention Center
Department of Epidemiology
College of Public Health
University of Iowa
Iowa City, IA 52242-2007
MedicalResearch: What are the main findings of the study?
Dr. Robinson: The PCSK9 antibody, evolocumab, reduced LDL (or bad) cholesterol by about 65-70% regardless of the dose or type of statin used. This is a greater percentage reduction than ezetimibe, another drug used to lower LDL cholesterol in statin-treated patients, which lowered LDL cholesterol 15-20%. Side effects of evolocumab were similar to those for ezetimibe or placebo.
14 May Statins Underutilized By Many Patients With Cardiovascular Risk
MedicalResearch.com Interview with Dr. Michael Johansen, MD, MS Department of Family Medicine The Ohio State University Columbus, OH 43201 MedicalResearch: What are the main findings of the study? Dr. Johansen: We found a surprisingly low number of people with coronary artery disease and diabetes (over age 40) were not reporting statin use. Of the people with coronary artery disease only 58% reported statin use while 52% of people with diabetes reported use. In addition, a reported diagnosis of hyperlipidemia was strongly correlated with statin use. In fact, individuals with hyperlipidemia and no coronary artery disease were more apt to be on a statin than people with coronary artery disease and no hyperlipidemia. Other high-risk conditions that have recently been included in the ACC/AHA high risk category were weakly or not associated with statin use including stroke and peripheral arterial disease.29 Apr Recent Statin Users Likely to Eat More and Gain Weight
MedicalResearch.com Interview with:
Takehiro Sugiyama, MD, MSHS, PhD
Project Director, Diabetes Policy Planning Office
Management and Planning Bureau
Fellow, Department of Diabetes, Endocrinology and Metabolism
National Center for Global Health and Medicine
Shinjuku-ku, Tokyo Japan
MedicalResearch.com: What are the main findings of the study?
Dr. Sugiyama: In the US nationally representative sample from the National Health and Nutrition Examination Survey 1999-2010, we found that statin users in 2009-2010 eat 9.6% more calories and 14.4% more fat than statin users in 1999-2000. These increases were not observed in statin non-users; the trends of caloric and fat intake were statistically different between statin users and non-users. In 1999-2000, caloric and fat intake was significantly less for statin users compared with non-users, but the difference between the groups because smaller as time went by and there was no statistical difference in 2009-2010. Body mass index increased more rapidly for statin users compared to non-users.
31 Mar Hyperlipidemia: Monoclonal Antibody Successfully Reduced LDL-C in One Year Trial
MedicalResearch.com Interview with:
Evan A. Stein, M.D., Ph.D. FRCP(C), FCAP
Metabolic and Atherosclerosis Research Center
Cincinnati, OH 45225,
MedicalResearch.com: What are the main findings of the study?
Dr. Stein: The study which is the first 52 week randomized double blind trial of a PCSK9 to report results (all others have been 12 weeks) demonstrated that the excellent LDL-C reductions of 55-60% seen at 12 weeks are maintained through 52 weeks, with no fall off in patient compliance, tolerability of efficacy. It also demonstrated that with longer treatment no new or unexpected side effects.
The study also had a unique design in that prior to randomization to the PCSK9 inhibitor (evolocumab) or placebo patients had a run in period during which time they were assigned, based on NCEP-ATP III criteria, to appropriated background therapy which ranged from diet only, to atorvastatin 10 mg a day, to atorvatatin 80 mg a day or atorvastatin 80 mg a day plus ezetimibe - reflecting how these patients are treated in practice. Only then if their LDL-C was still above 75 mg/dL were they randomized into the treatment part of the study with the new drug. The study showed that irrespective of background therapy the reduction with evolocumab was consistent.
29 Mar Statins and Sex
MedicalResearch.com Interview with:
Dr. John B. Kostis, MD
Chief of Medical Service, RWJUH
Professor of Medicine & Pharmacology
Chair - Department of Medicine
Rutgers Robert Wood Johnson
MedicalResearch.com: What are the main findings of the study?
Dr.Kostis: In this meta-analysis statins improved erectile function in men with decreased function on the average.
28 Mar New Statins Guidelines Will Prevent More Heart Attacks, Stroke But Treat More Who May Not Need Them
MedicalResearch.com Interview with:
Michael J. Pencina, PhD
Professor of Biostatistics and Bioinformatics
Director of Biostatistics
Duke Clinical Research Institute
Durham, NC 27710
MedicalResearch.com: What motivated your research?
Dr. Pencina: After the new guidelines were issued last November, we were intrigued by the change in treatment philosophy from that based on cholesterol levels (used by the “old guidelines” known as NCEP ATPIII) to one based on 10-year risk of cardiovascular disease (used by the new AHA-ACC guidelines). We were curious what the practical consequences of this shift would be.
Furthermore, the media quoted a lot of experts making educated guesses on the impact. We realized that this question can be answered much more precisely based on the NHANES data.
25 Nov Neurofibromatosis: Simvastatin for Cognitive Deficits
MedicalResearch.com Interview with:
Prof Ype Elgersma PhD
Professor, Neuroscience
Neuroscience Institute, Erasmus University Rotterdam
Rotterdam, Netherlands
MedicalResearch.com: What are the main findings of the study?
Answer: Research in genetic mouse models suggested that inhibition of HMG-CoA-reductase by statins might ameliorate the cognitive and behavioral phenotype of children with Neurofibromatosis type 1 (NF1), an autosomal dominant disorder. In a 12-month randomized placebo-controlled study including 84 children with NF1, we found that simvastatin, an inhibitor of the HMG-CoA-reductase pathway had no effect on full-scale intelligence, attention problems or internalizing behavioral problems, or on any of the secondary outcome measures.
27 May Risk of incident diabetes among patients treated with statins
MedicalResearch.com eInterview with Muhammad Mamdani Director, Applied Health Research Centre, St. Michael's Hospital Scientist in the Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael's Hospital Associate Professor, Department of Health Policy, Management, and Evaluation University of Toronto MedicalResearch.com: What are the main findings of this study? Our study examined over 470,000...
02 Apr Discontinuation of Statins in Routine Care Settings: A Cohort Study
MedicalResearch.com Interview Dr. Alexander Turchin M.D.,M.S.
Director of Informatics Research
Assistant Professor, Harvard Medical School
Endocrinology, Diabetes and Hypertension
Brigham and Women's Hospital Boston, MA
MedicalResearch.com: What are the main findings of the study?
Dr. Turchi: A large number of patients – 17% of individuals included in our study – report side effects to statins in routine care settings. Nearly 60% of these patients stopped the statin at least temporarily. However, overwhelming majority of patients who stopped taking a statin after experiencing a possible side effect, could tolerate a statin long-term if they tried taking one again. In other words, it appears that many statin-related events are tolerable, specific to individual statins or have other causes. These findings are consistent with the current guidelines that urge a conservative approach to statin discontinuation. They are particularly important because statins have been convincingly shown to save lives – they decrease all-cause mortality, and also cardiovascular mortality and incidence of cardiovascular events in patients with ischemic heart disease and / or elevated cholesterol levels.
- 1
- 2